In an attempt to determine whether and to what extent carbamazepine is teratogenic, we evaluated eight children whom we identified retrospectively as having had prenatal exposure to carbamazepine alone or in combination with a variety of anticonvulsants other than phenytoin. In addition, in a prospective study, we documented the outcome of the pregnancies of 72 women who contacted us early in pregnancy because they were concerned about the potential teratogenicity of carbamazepine. A pattern of malformation, the principal features of which are minor craniofacial defects and fingernail hypoplasia, and of developmental delay was identified in the eight children retrospectively ascertained to have been exposed to carbamazepine in utero; this pattern was subsequently confirmed through the evaluation of 48 children born alive to the women in the prospective study. That carbamazepine itself is teratogenic is indicated by the incidence of craniofacial defects (11 percent), fingernail hypoplasia (26 percent), and developmental delay (20 percent) in the 35 live-born children of the women in the prospective study who were exposed prenatally to carbamazepine alone. The similarity between the children exposed prenatally to carbamazepine and those with the fetal hydantoin syndrome is probably related to the fact that both drugs are metabolized through the arene oxide pathway and raises the possibility that it is the epoxide intermediate rather than the specific drug itself that is the teratogenic agent.
Source Information
Division of Dysmorphology, Department of Pediatrics, University of California-San Diego, La Jolla.
This article has been cited by other articles:
Kini, U, Adab, N, Vinten, J, Fryer, A, Clayton-Smith, J, on behalf of the Liverpool and Manchester Neurodev,
(2006). Dysmorphic features: an important clue to the diagnosis and severity of fetal anticonvulsant syndromes. Arch. Dis. Child. Fetal Neonatal Ed.
91: F90-F95
[Abstract][Full Text]
Yonkers, K. A., Wisner, K. L., Stowe, Z., Leibenluft, E., Cohen, L., Miller, L., Manber, R., Viguera, A., Suppes, T., Altshuler, L.
(2005). Management of Bipolar Disorder During Pregnancy The Postpartum Period. Focus
3: 266-279
[Abstract][Full Text]
Adab, N, Kini, U, Vinten, J, Ayres, J, Baker, G, Clayton-Smith, J, Coyle, H, Fryer, A, Gorry, J, Gregg, J, Mawer, G, Nicolaides, P, Pickering, L, Tunnicliffe, L, Chadwick, D W
(2004). The longer term outcome of children born to mothers with epilepsy. J. Neurol. Neurosurg. Psychiatry
75: 1575-1583
[Abstract][Full Text]
Yonkers, K. A., Wisner, K. L., Stowe, Z., Leibenluft, E., Cohen, L., Miller, L., Manber, R., Viguera, A., Suppes, T., Altshuler, L.
(2004). Management of Bipolar Disorder During Pregnancy and the Postpartum Period. Am. J. Psychiatry
161: 608-620
[Abstract][Full Text]
Costa, L. G., Steardo, L., Cuomo, V.
(2004). Structural Effects and Neurofunctional Sequelae of Developmental Exposure to Psychotherapeutic Drugs: Experimental and Clinical Aspects. Pharmacol. Rev.
56: 103-147
[Abstract][Full Text]
Bittigau, P., Sifringer, M., Genz, K., Reith, E., Pospischil, D., Govindarajalu, S., Dzietko, M., Pesditschek, S., Mai, I., Dikranian, K., Olney, J. W., Ikonomidou, C.
(2002). Antiepileptic drugs and apoptotic neurodegeneration in the developing brain. Proc. Natl. Acad. Sci. USA
99: 15089-15094
[Abstract][Full Text]
Poblano, A., Belmont, A., Sosa, J., Ibarra, J., Rosas, Y., Lopez, V., Garza, S.
(2002). Effects of Prenatal Exposure to Carbamazepine on Brainstem Auditory Evoked Potentials in Infants of Epileptic Mothers. J Child Neurol
17: 364-368
[Abstract]
Holmes, L B
(2002). The teratogenicity of anticonvulsant drugs: a progress report. J. Med. Genet.
39: 245-247
[Full Text]
Dean, J C S, Hailey, H, Moore, S J, Lloyd, D J, Turnpenny, P D, Little, J
(2002). Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth. J. Med. Genet.
39: 251-259
[Abstract][Full Text]
Holmes, L. B., Harvey, E. A., Coull, B. A., Huntington, K. B., Khoshbin, S., Hayes, A. M., Ryan, L. M.
(2001). The Teratogenicity of Anticonvulsant Drugs. NEJM
344: 1132-1138
[Abstract][Full Text]
Adab, N, Jacoby, A, Smith, D, Chadwick, D
(2001). Additional educational needs in children born to mothers with epilepsy. J. Neurol. Neurosurg. Psychiatry
70: 15-21
[Abstract][Full Text]
Moore, S J, Turnpenny, P, Quinn, A, Glover, S, Lloyd, D J, Montgomery, T, Dean, J C S
(2000). A clinical study of 57 children with fetal anticonvulsant syndromes. J. Med. Genet.
37: 489-497
[Abstract][Full Text]
Faiella, A., Wernig, M., Consalez, G. G., Hostick, U., Hofmann, C., Hustert, E., Boncinelli, E., Balling, R., Nadeau, J. H.
(2000). A mouse model for valproate teratogenicity: parental effects, homeotic transformations, and altered HOX expression. Hum Mol Genet
9: 227-236
[Abstract][Full Text]
Wintz, C. J. B.
(1999). Difficult Decisions: Women of Childbearing Age, Mental Illness, and Psychopharmacologic Therapy. J Am Psychiatr Nurses Assoc
5: 5-14
[Abstract]
Rubin, P.
(1998). Fortnightly review: Drug treatment during pregnancy. BMJ
317: 1503-1506
[Full Text]
Amore, B. M., Kalhorn, T. F., Skiles, G. L., Hunter, A. P., Bennett, G. D., Finnell, R. H., Nelson, S. D., Slattery, J. T.
(1997). Characterization of Carbamazepine Metabolism in a Mouse Model of Carbamazepine Teratogenicity. Drug Metab. Dispos.
25: 953-962
[Abstract][Full Text]
Brodie, M. J., Dichter, M. A.
(1996). Antiepileptic Drugs. NEJM
334: 168-175
[Full Text]
Taylor, M., Kumar, R.
(1994). Neuroleptics, oestrogen, post-partum psychiatric disturbance and movement disorder: a case report. J Psychopharmacol
8: 134-135
Legido, A., Toomey, K., Goldsmith, L.
(1991). Congenital Rib Anomalies In A Fetus Exposed To Carbamazepine. CLIN PEDIATR
30: 63-64
Previous
